within Pharmacolibrary.Drugs.ATC.M;

model M02AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 50 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) formerly used to treat pain and inflammation associated with conditions such as rheumatoid arthritis and ankylosing spondylitis in humans. Due to its risk of serious side effects, including bone marrow suppression and gastrointestinal complications, its use in humans has been discontinued or severely restricted in many countries. It is still used in veterinary medicine, particularly in horses.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adults after a single oral dose.</p><h4>References</h4><ol><li><p>Houck, EL, et al., &amp; Delk, KW (2022). Phenylbutazone pharmacokinetics in southern white rhinoceros (Ceratotherium simum simum) after oral administration. <i>Journal of veterinary pharmacology and therapeutics</i> 45(2) 196–202. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13036&quot;>10.1111/jvp.13036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34894412/&quot;>https://pubmed.ncbi.nlm.nih.gov/34894412</a></p></li><li><p>Aarbakke, J (1978). Clinical pharmacokinetics of phenylbutazone. <i>Clinical pharmacokinetics</i> 3(5) 369–380. DOI:<a href=&quot;https://doi.org/10.2165/00003088-197803050-00003&quot;>10.2165/00003088-197803050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/359213/&quot;>https://pubmed.ncbi.nlm.nih.gov/359213</a></p></li><li><p>Knych, HK, et al., &amp; Kass, PH (2019). Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. <i>Drug testing and analysis</i> 11(6) 792–803. DOI:<a href=&quot;https://doi.org/10.1002/dta.2553&quot;>10.1002/dta.2553</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30499176/&quot;>https://pubmed.ncbi.nlm.nih.gov/30499176</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M02AA01;
